Kohda Y, Hiramatsu R, Kuwahara K, Sato T
Third Department of Internal Medicine, Kumamoto University Medical School, Japan.
Nephron. 1994;66(1):71-5. doi: 10.1159/000187769.
Dialysate contents of 17-hydroxycorticosteroids (17-OHCS) in hemodialysis patients were studied as a potential measure of adrenocortical function. Dialysate 17-OHCS contents after a 2-day interval of hemodialysis in 15 hemodialysis patients were determined. Dialysate 17-OHCS increased after intravenous injection of cortisol the evening prior to hemodialysis (n = 4). Dialysate 17-OHCS content was suppressed, as was plasma cortisol, after a standard dexamethasone (Dex) suppression test (n = 1). Their plasma cortisol was suppressible or nonsuppressible by an overnight Dex suppression test, as reported previously. However, basal dialysate 17-OHCS contents were not different between them, indicating that the nonsuppressible patients with overnight Dex seem not to have hypercortisolism. We conclude that determination of dialysate 17-OHCS seems a useful noninvasive technique for the evaluation of adrenocortical function in hemodialysis patients.
对血液透析患者透析液中17-羟皮质类固醇（17-OHCS）的含量进行了研究，以此作为评估肾上腺皮质功能的一种潜在手段。测定了15例血液透析患者在间隔2天进行血液透析后的透析液17-OHCS含量。在血液透析前一晚静脉注射皮质醇后，透析液17-OHCS含量升高（n = 4）。在标准地塞米松（Dex）抑制试验后，透析液17-OHCS含量以及血浆皮质醇均受到抑制（n = 1）。如先前报道，通过过夜Dex抑制试验，他们的血浆皮质醇可被抑制或不可被抑制。然而，他们之间的基础透析液17-OHCS含量并无差异，这表明过夜Dex试验结果不可被抑制的患者似乎不存在皮质醇增多症。我们得出结论，测定透析液17-OHCS似乎是评估血液透析患者肾上腺皮质功能的一种有用的非侵入性技术。
